Recent Alzheimer’s Disease Neuroimaging Initiative (ADNI) data have shown that diabetic patients treated with metformin during early AD stages exhibited better cognitive performance and cerebrospinal fluid biomarker profiles, with treatment associated with higher amyloid beta and lower tau/phosphorylated tau levels [245]. The gene discussed is MAPT; the disease is Alzheimer disease.